DiscoverNEJM InterviewsNEJM at ESMO — Phase 3 Trial of Cabozantinib in Advanced Neuroendocrine Tumors
NEJM at ESMO — Phase 3 Trial of Cabozantinib in Advanced Neuroendocrine Tumors

NEJM at ESMO — Phase 3 Trial of Cabozantinib in Advanced Neuroendocrine Tumors

Update: 2024-09-15
Share

Description

Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

NEJM at ESMO — Phase 3 Trial of Cabozantinib in Advanced Neuroendocrine Tumors

NEJM at ESMO — Phase 3 Trial of Cabozantinib in Advanced Neuroendocrine Tumors